Pharmaceuticals, Biotechnology and Life Sciences
PMV Pharmaceuticals, Inc., a cancer focused developer of p53-targeted small molecule drugs, has completed a Series B financing round bagging $74 million.
BD said on Wednesday that its BD Veritor System Flu A+B, a digital immunoassay for the rapid detection of influenza, meets the new Food and Drug Administration’s (FDA’s) performance requirements.
Superbug bacteria found in people, animals and food across the European Union pose an “alarming” threat to public and animal health having evolved to resist widely used antibiotics, disease and safety experts warned on Wednesday.
A UK-based private clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) for the treatment of chronic inflammatory gastrointestinal (GI) and ocular diseases, has triggered the phase 1/2a proof of concept study in the US of TOP1630 ophthalmic solution for the treatment of the dry eye syndrome.
Verona Pharma has made an important step in the phase two clinical trial for its candidate RPL554, used for chronic obstructive pulmonary disease (COPD). Namely, the first patient has been dosed testing RPL544 as an add-on therapy to tiotropium, Spiriva.
Bayer has reported net income of €4,531 million which is 10.2% increase comparing to 2015 (€4,110 million). The company reported earnings growth in pharmaceutical activities, while other activities remain steady.
Arix Bioscience’s issued ordinary shares have on Wednesday been admitted to the Official List of the UK Listing Authority and to trading on the London Stock Exchange’s main market for listed securities under the ticker “ARIX”.
Advanced Oncotherapy, the developer of next generation proton therapy systems for cancer treatment, has secured a flexible and staged £26 million financing agreement with Bracknor Investment Group, a Dubai-based investment firm.
What does a healthy heart really mean? Is it just the physical heart muscle that matters, or is there an important emotional component?
And can the simple act of conveying your best wishes and intentions make a real difference in the health of the recipient’s heart — and even your own? What does the science say?
Bristol-Myers Squibb has entered into an ASR program with each of Morgan Stanley & Co. LLC and Goldman, Sachs & Co. to repurchase, in aggregate, $2 billion of Bristol-Myers Squibb’s common stock, and it has named three new directors.